Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Air (NASDAQ: XAIR) reported fiscal Q1 2025 results, showing a 45% revenue increase compared to the previous quarter. The company reiterated its FY 2025 revenue guidance of at least $10 million. Key highlights include:
- LungFit PH commercial execution strengthening, with devices used in over 55 hospitals across 10 U.S. states
- More than $7 million in aggregate contracted revenue through FY 2027
- Amir Avniel appointed CEO of NeuroNOS, focusing on neurological disorders
- Implemented capital conservation strategy, reducing headcount by over 25% since January 2024
- Q1 FY2025 revenue: $0.7 million; Net loss: ($12.2) million or ($0.27) per share
- Cash position: $21.4 million as of June 30, 2024
Beyond Air (NASDAQ: XAIR) has published a peer-reviewed article in Scientific Reports, demonstrating the safety and benefits of nitric oxide (NO) as an adjunct therapy for viral pneumonia. The study, conducted on COVID-19 patients, showed that 150-ppm intermittent inhaled NO administered with the LungFit® PRO device was well-tolerated and beneficial compared to usual care. Key findings include:
1. Mitigation of viral pneumonia severity
2. Enhanced recovery with reduced time to reach stable room air saturation
3. Shortened duration of supportive oxygen need
The company views these results as promising for further investigation of inhaled NO in treating viral and bacterial lung infections. Beyond Air is currently focusing on commercializing LungFit PH for treating term and near-term neonates with hypoxic respiratory failure.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company, has announced it will report its first fiscal quarter 2025 financial results on Tuesday, August 6, 2024, after the market closes. The company focuses on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors (through its affiliate Beyond Cancer, ). The financial results will cover the period ended June 30, 2024.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company, has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The event is scheduled for August 5-6, 2024. Steve Lisi, Chairman and CEO of Beyond Air, will be available for one-on-one meetings during the conference.
Beyond Air focuses on harnessing the power of nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company's affiliate, Beyond Cancer, is involved in cancer treatment research. Interested parties can contact their BTIG representative to schedule meetings with the Beyond Air team during the conference.
Beyond Air (NASDAQ: XAIR) reported its financial results for the fiscal fourth quarter and full year 2024, alongside a corporate update. The company appointed David Webster as Chief Commercial Officer and upgraded their LungFit PH device. The device has been utilized in over 50 hospitals, treating more than 1,100 patients. However, FY 2025 revenue guidance was revised to over $10M, down from $12M-$16M. Cost-cutting measures were implemented, reducing headcount by over 20%, and some R&D projects were paused. Net loss for FY 2024 was $60.2M, compared to $55.8M in FY 2023. The company expects to be cash flow positive by Q4 2026 and has $34.5M in cash and equivalents as of March 31, 2024. A conference call is scheduled for June 24, 4:30 PM ET.
Beyond Air, a company specializing in medical devices and biopharmaceuticals, has appointed David Webster as Chief Commercial Officer, effective July 8, 2024. Webster brings over 20 years of executive experience in the life sciences industry, including roles at Body Vision Medical and NeuroLogica. His appointment comes as Beyond Air's product, LungFit PH, is set to lead the nitric oxide (NO) market, with promising customer feedback and market engagement. The company granted Webster an inducement stock option to purchase 125,000 shares, vesting over four years. Webster's expertise is expected to drive significant market share gains for LungFit PH.
Beyond Cancer has revealed promising Phase 1a clinical data for their ultra-high concentration nitric oxide (UNO) platform, showing early tumor responses and immune system activation in subjects with relapsed or refractory unresectable solid tumors.
Data presented at the 2024 American Society of Clinical Oncology Annual Meeting highlighted immune biomarker responses, including increases in dendritic cells, cytotoxic T-cells, and central memory T-cells, along with a decrease of 54% in Myeloid Derived Suppressor Cells (MDSCs) post-treatment.
The Phase 1b trial, combining UNO with anti-PD-1 therapy, has been filed for regulatory approval and aims to enroll up to 20 subjects. UNO was generally well-tolerated, with primarily Grade 1 toxicities and one Grade 3 adverse event noted.
Beyond Air (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company, will announce its fiscal year-end 2024 financial results on June 24, 2024. The company, specializing in nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors, will host a conference call and webcast at 4:30 pm ET on the same day. The call can be accessed domestically at 1-877-407-0784 and internationally at 1-201-689-8560 using Conference ID: 13746892. A live and replay webcast will be available on the company's website.
Beyond Cancer, has been chosen to present on the clinical development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting. The company will host an event in Chicago featuring key opinion leaders to discuss the ongoing clinical development of UNO. Additionally, presentations at the ASCO Annual Meeting will showcase new data from the Phase 1 trial evaluating UNO101 in various malignancies.
Summary not available.